1.  24
    Aidan Hollis (2008). The Health Impact Fund: A Useful Supplement to the Patent System? Public Health Ethics 1 (2):124-133.
    Department of Economics, University of Calgary, 2500 University Dr NW, Calgary AB, T2N 1N4, Canada. Tel.: +1403220 5861; Fax: +1403220 5861; Email: ahollis{at}ucalgary.ca ' + u + '@' + d + ' '//--> . Abstract The Health Impact Fund has been proposed as an optional, comprehensive advance market commitment system offering financial payments or ‘prizes’ to patentees of new drugs, which are sold globally at an administered low price. The Fund is designed to offer payments based on the therapeutic impact (...)
    Direct download (12 more)  
    Export citation  
    My bibliography   6 citations  
  2.  3
    Sean Flynn, Aidan Hollis & Mike Palmedo (2009). An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries. Journal of Law, Medicine & Ethics 37 (2):184-208.
    This paper offers an economic rationale for compulsory licensing of needed medicines in developing countries. The patent system is based on a trade-off between the “deadweight losses” caused by market power and the incentive to innovate created by increased profits from monopoly pricing during the period of the patent. However, markets for essential medicines under patent in developing countries with high income inequality are characterized by highly convex demand curves, producing large deadweight losses relative to potential profits when monopoly firms (...)
    Direct download (3 more)  
    Export citation  
    My bibliography   4 citations  
  3.  5
    Thomas Pogge & Aidan Hollis (2011). Epilogue: New Drugs for Neglected Diseases. Cambridge Quarterly of Healthcare Ethics 20 (2):329-334.
    In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion or $2.65 billion.
    Direct download (7 more)  
    Export citation  
    My bibliography